Aardvark Therapeutics (AARD) 주식 개요는 임상 단계의 바이오 제약 회사로, 대사 질환 치료를 위해 타고난 항상성 경로를 활성화하는 저분자 치료제를 개발하는 데 주력하고 있습니다. 자세히 보기AARD 펀더멘털 분석스노우플레이크 점수가치 평가2/6미래 성장0/6과거 실적0/6재무 건전성6/6배당0/6위험 분석수익이 USD$1m 미만입니다($0)지난 3개월 동안 주가 변동성이 US 시장과 비교했을 때 매우 높았습니다.의미 있는 시가총액이 없습니다($94M)현재 수익성이 없으며 향후 3년 동안 수익을 낼 것으로 예상되지 않습니다.모든 위험 점검 보기AARD Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$4.51해당 없음내재 할인율Est. Revenue$PastFuture-70m142016201920222025202620282031Revenue US$14.2Earnings US$2.1AdvancedSet Fair ValueView all narrativesAardvark Therapeutics, Inc. 경쟁사Cognition TherapeuticsSymbol: NasdaqCM:CGTXMarket cap: US$115.3mRevium RxSymbol: OTCPK:RVRCMarket cap: US$102.4mLeonaBioSymbol: NasdaqCM:LONAMarket cap: US$94.8mVerrica PharmaceuticalsSymbol: NasdaqCM:VRCAMarket cap: US$103.4m가격 이력 및 성과Aardvark Therapeutics 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가US$4.5152주 최고가US$17.9452주 최저가US$3.35베타01개월 변동-16.01%3개월 변동-63.39%1년 변동-54.95%3년 변동n/a5년 변동n/aIPO 이후 변동-68.48%최근 뉴스 및 업데이트Seeking Alpha • May 18Aardvark Therapeutics: Regulatory Uncertainty Clouds ARD-101 Path ForwardSummary Aardvark Therapeutics, Inc. faces a pivotal regulatory setback as the FDA placed a clinical hold on ARD-101 due to unexpected cardiac signals. AARD now trades as a cash-backed option, with the stock reflecting little value beyond its $91M cash position and a 1.15x price-to-book ratio. Unblinding pivotal trial data could provide rapid safety clarity, but risks trial integrity and likely necessitates an additional confirmatory Phase 3 study. I maintain a neutral/hold stance on AARD until there is clearer FDA guidance, as regulatory resolution is the critical near-term catalyst. Read the full article on Seeking AlphaPrice Target Changed • May 17Price target decreased by 8.6% to US$15.44Down from US$16.90, the current price target is an average from 9 analysts. New target price is 238% above last closing price of US$4.57. Stock is down 54% over the past year. The company is forecast to post a net loss per share of US$3.74 next year compared to a net loss per share of US$2.93 last year.공시 • May 16Aardvark Therapeutics, Inc. Plans To Unblind HERO And OLE Data To Inform Path Forward Following FDA Clinical HoldAardvark Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has placed a full clinical hold on its investigational new drug application (IND) for ARD-101 related to the Company’s previously announced voluntary pause. The clinical hold applies to all ongoing clinical studies under the IND, including the Phase 3 HERO trial (AVK-101-301) evaluating ARD-101 for the treatment of hyperphagia in patients with Prader-Willi Syndrome (PWS) and the Phase 3 open-label extension (OLE) trial (AVK-101-302). The Company remains in active discussions with the FDA to support resolution of the clinical hold and determine a path forward for the ARD-101 program. In parallel with its ongoing engagement with the FDA, Aardvark intends to unblind the clinical data accumulated to date across both the HERO trial and the OLE trial to assess the totality of available efficacy and safety data and to support an informed determination of next steps for the ARD-101 program. As of February 27, 2026, Aardvark had dosed 68 patients in the randomized controlled HERO trial and 19 patients in the OLE trial. As of March 31, 2026, Aardvark held $91.2 million in cash, cash equivalents and short-term investments, which the Company believes is sufficient to fund projected operations into mid-2027. ARD-101 is an oral, small-molecule therapeutic designed to stimulate the release of gut-peptide hormones through activation of bitter taste receptors. ARD-101 was being evaluated in the Phase 3 HERO trial as a treatment for hyperphagia associated with Prader-Willi Syndrome, a rare genetic disorder characterized by insatiable hunger.공시 • Mar 24Aardvark Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.Aardvark Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $150 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market OfferingNew Risk • Mar 22New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$88.6m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$126m net loss in 3 years). Market cap is less than US$100m (US$88.6m market cap).New Risk • Mar 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 21% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Revenue is less than US$1m. Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$126m net loss in 3 years).더 많은 업데이트 보기Recent updatesSeeking Alpha • May 18Aardvark Therapeutics: Regulatory Uncertainty Clouds ARD-101 Path ForwardSummary Aardvark Therapeutics, Inc. faces a pivotal regulatory setback as the FDA placed a clinical hold on ARD-101 due to unexpected cardiac signals. AARD now trades as a cash-backed option, with the stock reflecting little value beyond its $91M cash position and a 1.15x price-to-book ratio. Unblinding pivotal trial data could provide rapid safety clarity, but risks trial integrity and likely necessitates an additional confirmatory Phase 3 study. I maintain a neutral/hold stance on AARD until there is clearer FDA guidance, as regulatory resolution is the critical near-term catalyst. Read the full article on Seeking AlphaPrice Target Changed • May 17Price target decreased by 8.6% to US$15.44Down from US$16.90, the current price target is an average from 9 analysts. New target price is 238% above last closing price of US$4.57. Stock is down 54% over the past year. The company is forecast to post a net loss per share of US$3.74 next year compared to a net loss per share of US$2.93 last year.공시 • May 16Aardvark Therapeutics, Inc. Plans To Unblind HERO And OLE Data To Inform Path Forward Following FDA Clinical HoldAardvark Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has placed a full clinical hold on its investigational new drug application (IND) for ARD-101 related to the Company’s previously announced voluntary pause. The clinical hold applies to all ongoing clinical studies under the IND, including the Phase 3 HERO trial (AVK-101-301) evaluating ARD-101 for the treatment of hyperphagia in patients with Prader-Willi Syndrome (PWS) and the Phase 3 open-label extension (OLE) trial (AVK-101-302). The Company remains in active discussions with the FDA to support resolution of the clinical hold and determine a path forward for the ARD-101 program. In parallel with its ongoing engagement with the FDA, Aardvark intends to unblind the clinical data accumulated to date across both the HERO trial and the OLE trial to assess the totality of available efficacy and safety data and to support an informed determination of next steps for the ARD-101 program. As of February 27, 2026, Aardvark had dosed 68 patients in the randomized controlled HERO trial and 19 patients in the OLE trial. As of March 31, 2026, Aardvark held $91.2 million in cash, cash equivalents and short-term investments, which the Company believes is sufficient to fund projected operations into mid-2027. ARD-101 is an oral, small-molecule therapeutic designed to stimulate the release of gut-peptide hormones through activation of bitter taste receptors. ARD-101 was being evaluated in the Phase 3 HERO trial as a treatment for hyperphagia associated with Prader-Willi Syndrome, a rare genetic disorder characterized by insatiable hunger.공시 • Mar 24Aardvark Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.Aardvark Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $150 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market OfferingNew Risk • Mar 22New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$88.6m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$126m net loss in 3 years). Market cap is less than US$100m (US$88.6m market cap).New Risk • Mar 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 21% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Revenue is less than US$1m. Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$126m net loss in 3 years).Price Target Changed • Mar 02Price target decreased by 9.8% to US$29.60Down from US$32.80, the current price target is an average from 5 analysts. New target price is 441% above last closing price of US$5.47. Stock is down 57% over the past year. The company is forecast to post a net loss per share of US$2.93 next year compared to a net loss per share of US$5.15 last year.공시 • Feb 28Aardvark Therapeutics Announces Voluntary Pause of Phase 3 Hero Trial in Prader-Willi SyndromeAardvark Therapeutics, Inc. announced it is voluntarily pausing the Phase 3 Hunger Elimination or Reduction Objective (HERO) trial. The HERO trial is a Phase 3 randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of ARD-101 as a treatment for hyperphagia in patients with Prader-Willi Syndrome (PWS). Based on the ongoing activities in the ARD-101 program, Aardvark no longer anticipates announcing topline data from the HERO trial in the third quarter of 2026 and expects to provide further guidance in the second quarter of this year. ARD-101 has demonstrated an ability to reduce hunger when used alone or in combination with currently available GLP-1 therapies. The FDA has granted ARD-101 both Orphan Drug Designation and Rare Pediatric Disease Designation for Prader-Willi Syndrome.공시 • Feb 12Aardvark Therapeutics, Inc. Announces Appointment of Executive, Effective February 9, 2026Aardvark Therapeutics, Inc. announced the appointment of Derrick C. Li as Chief Business Officer, as well as the expansion of Nelson Sun’s role to include Chief Operating Officer, in addition to his current role as Chief Financial Officer. The appointments are effective as of February 9, 2026. In Mr. Li’s new role, he will lead Aardvark's business development strategy and execution with responsibility for financing, licensing, partnership strategy and corporate development initiatives. Mr. Li is a seasoned biotechnology executive with more than 20 years of global experience in biopharmaceutical business development, investment banking and corporate strategy. Prior to joining Aardvark, he served as Chief Strategy Officer at ODC Life Sciences, a Latin America-focused clinical research organization, where he drove growth strategy and global partnerships. He has also held senior leadership roles, including Head of Strategy and Investor Relations at Cellular Biomedicine Group (now AbelZeta). Additionally, he has extensive investment banking and investment management experience, most recently, serving as a Managing Director in the Healthcare Investment Group at Robert W. Baird. Mr. Li earned a dual bachelor's degree in accountancy and finance from Villanova University.공시 • Feb 10Aardvark Therapeutics Announces Fda Submission and Irb Approval of Amended Trial Protocol for Lead Candidate Ard-101, Expanding Eligibility in Phase 3 Study of Prader-Willi SyndromeAardvark Therapeutics, Inc. announced that Institutional Review Board (IRB) approval has been granted in the United States for an amended protocol to its ongoing Phase 3 HERO pivotal clinical trial evaluating ARD-101 for the treatment of hyperphagia in individuals with Prader-Willi Syndrome (PWS). The amended protocol, submitted to the U.S. Food and Drug Administration (FDA), lowers the minimum age of eligibility for trial participation from 10 to 7 years old. This protocol amendment reflects Aardvark's continued focus on reducing barriers to participation and expanding access for those affected by PWS, a rare genetic disorder characterized by chronic hyperphagia. Expanding eligibility reflects Aardvark's commitment to addressing the urgent need in the PWS community for a differentiated therapy and aim to ensure broad and equitable access. The Hunger Elimination or Reduction Objective (HERO) trial (NCT06828861) is a Phase 3 randomized, double-blind, placebo-controlled trial assessing ARD-101 for thetreatment of hyperphagia in patients with Prader-Willi syndrome (PWS). Aardvark plans to enroll 90 patients in this clinical trial across the U.S., Australia, Canada, the United Kingdom and South Korea. The primary endpoint is change in the Hyperphagia Questionnaire for Clinical Trials (HQ-CT) score from baseline to Week 12. Secondary outcome measures include change in Caregiver Global Impression of Severity (CaGI-S) for hyperphagia in PWS patients and change in Clinical Global Impression of Severity ("CGI-S") score for hyperphagia inPWS patients. All participants who complete the 12-week clinical trial will have the option to participate in an Open Label Extension trial. More information about the study can be found at <URL> The FDA has granted ARD-101 both Orphan Drug Designation and Rare Pediatric Disease Designation for Prader-Willi Syndrome ("PWS"). ARD-101 is being evaluated in the Phase 3 HERO trial for hyperphagia associated with PWS associated with PWS.Recent Insider Transactions • Dec 15CEO, Secretary & Director recently bought US$101k worth of stockOn the 11th of December, Tien-Li Lee bought around 7k shares on-market at roughly US$14.49 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Tien-Li has been a buyer over the last 12 months, purchasing a net total of US$359k worth in shares.공시 • Dec 11Aardvark Therapeutics Announces First Patient Dosed in Australia in Hero Phase 3 Trial for Prader-Willi SyndromeAardvark Therapeutics, Inc. announced that the first patient has been dosed in Australia in its Phase 3 HERO pivotal clinical trial assessing ARD-101 for the treatment of hyperphagia in individuals with Prader-Willi syndrome (PWS). Additionally, regulatory clearance for enrollment by clinical trial sites in Canada and the United Kingdom has also been received. Based on strong enrollment in the US and continued progress in advancing the clinical trial internationally, the clinical trial continues to track towards a topline data readout in third quarter 2026. US trial sites are actively enrolling, and sites in Australia started enrolling in November. The Hunger Elimination or Reduction Objective (HERO) trial (NCT06828861) is a Phase 3 randomized, double-blind, placebo-controlled trial assessing ARD-101 For the treatment of hyperphagIA in patients with Prader-Willi Syndrome (PWS). Aardvark plans to enroll 90 patients in this clinical trial across the US, Australia, Canada, the United Kingdom, and South Korea. The primary endpoint is change in the Hyperphagia Questionnaire for Clinical Trials (HQ-CT) score from baseline to Week 12. Secondary outcome measures include change in Caregiver Global Impression of Severity (CaGI-S) for hyperphagia in PWS patients and change in Clinical Global Impression of Severity ("CGI-S") score for hyperphagia inPWS patients. ARD-101 has demonstrated an ability to reduce hunger when used alone or in combination with currently available GLP-1 therapies. The FDA has granted ARD-101 both Orphan Drug Designation and Rare Pediatric Disease Designation for PWS. ARD-101 is being evaluated in the Phase 3 HERO trial for hyperphagia associated with PWS associated with PWS.공시 • Nov 05Aardvark Therapeutics, Inc. Presents Data Supporting its Metabolic Obesity Pipeline Programs at ObesityWeek 2025Aardvark Therapeutics, Inc. presented data at the ObesityWeek 2025 conference demonstrating the mechanistic rationale and therapeutic potential of two of its metabolic obesity programs, including ARD-201. Preclinical - ARD-201 (Validated Diet-Induced Obesity (DIO) Mouse Model): ARD-201 reduced fat mass comparable to high-dose tirzepatide but, unlike tirzepatide, preserved lean mass; ARD-201 alone achieved glucose control comparable to high-dose tirZepatide, and in combination with low-dose tirzepatides delivered the most rapid glucose clearance; Previously reported preclinical data demonstrated ARD-201 reduced body weight by 19% after 30 days, which was comparable to high-dose tir Zepatide; Previously reported preclinical data demonstrates ARD-201 ~30% weight loss when combined low-dose dirzepatide; Clinical - ARD-101 (Randomized, Placebo-Controlled, Phase 2A Study in Adults with Obesity): ARD-101 showed signals of weight control, reduced hunger, and improved metabolic parameters, particularly among participants with elevated baseline values; ARD-101 was well tolerated, with no serious adverse events or treatment discontinuations, reflecting a distinct profile from the effects associated with current anti-obesity therapies; WE-868 is a small molecule isoflavonoid designed to modulate oxidative phosphorylation and represents a potentially novel pathway for promoting weight loss and additional metabolic benefits: In preclinical studies, WE-868 dose-dependently prevented high-fat diet (HFD)-induced weight gain, with the higher dose inducing net weight loss; In DIO mice, significant weight loss was seen in medium and high dose WE-868 compared to semaglutide.공시 • Oct 08Aardvark Therapeutics Announces Fda Alignment on Protocol Amendment Expanding Phase 3 Hero Trial Population for Prader-Willi SyndromeAardvark Therapeutics, Inc. announced alignment with the U.S. Food and Drug Administration (FDA) on a protocol amendment to the company's Phase 3 HERO trial of ARD-101 for the treatment of hyperphagia associated with Prader-Willi Syndrome (PWS). The protocol amendment changes the minimum age of eligibility to participate in the trial from 13 to 10 years old. ARD-101 has demonstrated an ability to reduce hunger when used alone or in combination with currently available GLP-1 therapies. The FDA has granted ARD-101 both Orphan Drug Designation and Rare Pediatric Disease Designation for PWS. ARD-101 is being evaluated in the Phase 3 HERO trial for hyperphagia associated with PWS associated with PWS.Recent Insider Transactions • Sep 14CEO, Secretary & Director recently bought US$161k worth of stockOn the 12th of September, Tien-Li Lee bought around 20k shares on-market at roughly US$8.03 per share. This transaction amounted to 1.3% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Tien-Li's only on-market trade for the last 12 months.Recent Insider Transactions Derivative • Sep 01CEO, Secretary & Director exercised options to buy US$143k worth of stock.On the 28th of August, Tien-Li Lee exercised options to buy 17k shares at a strike price of around US$4.24, costing a total of US$73k. This transaction amounted to 1.2% of their direct individual holding at the time of the trade. Since December 2024, Tien-Li's direct individual holding has decreased from 2.91m shares to 1.51m. This was the only transaction from an insider over the last 12 months.공시 • Aug 12Aardvark Therapeutics, Inc. Announces ARD-201 Preclinical Obesity Data Showing Significant Weight Loss as A Monotherapy, Enhancement of Glp-1Ra Therapy in Combination, and Effective Maintenance Following Discontinuation of Glp-1Ra TherapyAardvark Therapeutics, Inc. announced new positive preclinical data demonstrating the potential of ARD-201 for the treatment of metabolic obesity and obesity-related conditions. Data in the validated diet-induced obesity (DIO) mouse model (a conventional model recognized for its strong translational relevance in the field of glucagon-like peptide-1 receptor agonists (GLP-1RAs)) demonstrated potential applications for ARD-201, including for the attenuation of weight gain after withdrawal from GLP-1RA therapies, as a monotherapy for weight loss without GLP-1RA therapy, as well as for weight loss in combination with GLP-1RA therapy. These two focused trials will replace the previously planned EMPOWER trial and are designed to enhance the precision and clarity of data collection compared to the EMPOWER trial.공시 • Feb 14Aardvark Therapeutics, Inc. has completed an IPO in the amount of $94.208 million.Aardvark Therapeutics, Inc. has completed an IPO in the amount of $94.208 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 5,888,000 Price\Range: $16 Discount Per Security: $1.12 Transaction Features: Reserved Share Offering; Sponsor Backed Offering주주 수익률AARDUS PharmaceuticalsUS 시장7D-33.0%-0.1%-0.3%1Y-54.9%38.7%26.7%전체 주주 수익률 보기수익률 대 산업: AARD은 지난 1년 동안 38.7%의 수익을 기록한 US Pharmaceuticals 산업보다 저조한 성과를 냈습니다.수익률 대 시장: AARD은 지난 1년 동안 26.7%를 기록한 US 시장보다 저조한 성과를 냈습니다.주가 변동성Is AARD's price volatile compared to industry and market?AARD volatilityAARD Average Weekly Movement22.2%Pharmaceuticals Industry Average Movement10.0%Market Average Movement7.2%10% most volatile stocks in US Market16.2%10% least volatile stocks in US Market3.2%안정적인 주가: AARD의 주가는 지난 3개월 동안 US 시장보다 변동성이 컸습니다.시간에 따른 변동성: AARD의 주간 변동성은 지난 1년간 16%에서 22%로 증가했습니다.회사 소개설립직원 수CEO웹사이트201740Tien-Li Leeaardvarktherapeutics.com임상 단계의 바이오 제약 회사인 Aardvark Therapeutics는 대사 질환 치료를 위해 타고난 항상성 경로를 활성화하는 저분자 치료제를 개발하는 데 주력하고 있습니다. 는 2017년에 설립되었으며 캘리포니아주 샌디에이고에 본사를 두고 있습니다.더 보기Aardvark Therapeutics, Inc. 기초 지표 요약Aardvark Therapeutics의 순이익과 매출은 시가총액과 어떻게 비교됩니까?AARD 기초 통계시가총액US$93.59m순이익 (TTM)-US$69.87m매출 (TTM)n/a0.0x주가매출비율(P/S)-1.4x주가수익비율(P/E)AARD는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표AARD 손익계산서 (TTM)매출US$0매출원가US$0총이익US$0기타 비용US$69.87m순이익-US$69.87m최근 보고된 실적Mar 31, 2026다음 실적 발표일해당 없음주당순이익(EPS)-3.20총이익률0.00%순이익률0.00%부채/자본 비율0%AARD의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/21 01:05종가2026/05/21 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Aardvark Therapeutics, Inc.는 12명의 분석가가 다루고 있습니다. 이 중 10명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Tazeen AhmadBofA Global ResearchWilliam WoodB. Riley Securities, Inc.Suranjit MukherjeeBTIG9명의 분석가 더 보기
Seeking Alpha • May 18Aardvark Therapeutics: Regulatory Uncertainty Clouds ARD-101 Path ForwardSummary Aardvark Therapeutics, Inc. faces a pivotal regulatory setback as the FDA placed a clinical hold on ARD-101 due to unexpected cardiac signals. AARD now trades as a cash-backed option, with the stock reflecting little value beyond its $91M cash position and a 1.15x price-to-book ratio. Unblinding pivotal trial data could provide rapid safety clarity, but risks trial integrity and likely necessitates an additional confirmatory Phase 3 study. I maintain a neutral/hold stance on AARD until there is clearer FDA guidance, as regulatory resolution is the critical near-term catalyst. Read the full article on Seeking Alpha
Price Target Changed • May 17Price target decreased by 8.6% to US$15.44Down from US$16.90, the current price target is an average from 9 analysts. New target price is 238% above last closing price of US$4.57. Stock is down 54% over the past year. The company is forecast to post a net loss per share of US$3.74 next year compared to a net loss per share of US$2.93 last year.
공시 • May 16Aardvark Therapeutics, Inc. Plans To Unblind HERO And OLE Data To Inform Path Forward Following FDA Clinical HoldAardvark Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has placed a full clinical hold on its investigational new drug application (IND) for ARD-101 related to the Company’s previously announced voluntary pause. The clinical hold applies to all ongoing clinical studies under the IND, including the Phase 3 HERO trial (AVK-101-301) evaluating ARD-101 for the treatment of hyperphagia in patients with Prader-Willi Syndrome (PWS) and the Phase 3 open-label extension (OLE) trial (AVK-101-302). The Company remains in active discussions with the FDA to support resolution of the clinical hold and determine a path forward for the ARD-101 program. In parallel with its ongoing engagement with the FDA, Aardvark intends to unblind the clinical data accumulated to date across both the HERO trial and the OLE trial to assess the totality of available efficacy and safety data and to support an informed determination of next steps for the ARD-101 program. As of February 27, 2026, Aardvark had dosed 68 patients in the randomized controlled HERO trial and 19 patients in the OLE trial. As of March 31, 2026, Aardvark held $91.2 million in cash, cash equivalents and short-term investments, which the Company believes is sufficient to fund projected operations into mid-2027. ARD-101 is an oral, small-molecule therapeutic designed to stimulate the release of gut-peptide hormones through activation of bitter taste receptors. ARD-101 was being evaluated in the Phase 3 HERO trial as a treatment for hyperphagia associated with Prader-Willi Syndrome, a rare genetic disorder characterized by insatiable hunger.
공시 • Mar 24Aardvark Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.Aardvark Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $150 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering
New Risk • Mar 22New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$88.6m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$126m net loss in 3 years). Market cap is less than US$100m (US$88.6m market cap).
New Risk • Mar 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 21% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Revenue is less than US$1m. Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$126m net loss in 3 years).
Seeking Alpha • May 18Aardvark Therapeutics: Regulatory Uncertainty Clouds ARD-101 Path ForwardSummary Aardvark Therapeutics, Inc. faces a pivotal regulatory setback as the FDA placed a clinical hold on ARD-101 due to unexpected cardiac signals. AARD now trades as a cash-backed option, with the stock reflecting little value beyond its $91M cash position and a 1.15x price-to-book ratio. Unblinding pivotal trial data could provide rapid safety clarity, but risks trial integrity and likely necessitates an additional confirmatory Phase 3 study. I maintain a neutral/hold stance on AARD until there is clearer FDA guidance, as regulatory resolution is the critical near-term catalyst. Read the full article on Seeking Alpha
Price Target Changed • May 17Price target decreased by 8.6% to US$15.44Down from US$16.90, the current price target is an average from 9 analysts. New target price is 238% above last closing price of US$4.57. Stock is down 54% over the past year. The company is forecast to post a net loss per share of US$3.74 next year compared to a net loss per share of US$2.93 last year.
공시 • May 16Aardvark Therapeutics, Inc. Plans To Unblind HERO And OLE Data To Inform Path Forward Following FDA Clinical HoldAardvark Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has placed a full clinical hold on its investigational new drug application (IND) for ARD-101 related to the Company’s previously announced voluntary pause. The clinical hold applies to all ongoing clinical studies under the IND, including the Phase 3 HERO trial (AVK-101-301) evaluating ARD-101 for the treatment of hyperphagia in patients with Prader-Willi Syndrome (PWS) and the Phase 3 open-label extension (OLE) trial (AVK-101-302). The Company remains in active discussions with the FDA to support resolution of the clinical hold and determine a path forward for the ARD-101 program. In parallel with its ongoing engagement with the FDA, Aardvark intends to unblind the clinical data accumulated to date across both the HERO trial and the OLE trial to assess the totality of available efficacy and safety data and to support an informed determination of next steps for the ARD-101 program. As of February 27, 2026, Aardvark had dosed 68 patients in the randomized controlled HERO trial and 19 patients in the OLE trial. As of March 31, 2026, Aardvark held $91.2 million in cash, cash equivalents and short-term investments, which the Company believes is sufficient to fund projected operations into mid-2027. ARD-101 is an oral, small-molecule therapeutic designed to stimulate the release of gut-peptide hormones through activation of bitter taste receptors. ARD-101 was being evaluated in the Phase 3 HERO trial as a treatment for hyperphagia associated with Prader-Willi Syndrome, a rare genetic disorder characterized by insatiable hunger.
공시 • Mar 24Aardvark Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.Aardvark Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $150 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering
New Risk • Mar 22New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$88.6m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$126m net loss in 3 years). Market cap is less than US$100m (US$88.6m market cap).
New Risk • Mar 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 21% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Revenue is less than US$1m. Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$126m net loss in 3 years).
Price Target Changed • Mar 02Price target decreased by 9.8% to US$29.60Down from US$32.80, the current price target is an average from 5 analysts. New target price is 441% above last closing price of US$5.47. Stock is down 57% over the past year. The company is forecast to post a net loss per share of US$2.93 next year compared to a net loss per share of US$5.15 last year.
공시 • Feb 28Aardvark Therapeutics Announces Voluntary Pause of Phase 3 Hero Trial in Prader-Willi SyndromeAardvark Therapeutics, Inc. announced it is voluntarily pausing the Phase 3 Hunger Elimination or Reduction Objective (HERO) trial. The HERO trial is a Phase 3 randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of ARD-101 as a treatment for hyperphagia in patients with Prader-Willi Syndrome (PWS). Based on the ongoing activities in the ARD-101 program, Aardvark no longer anticipates announcing topline data from the HERO trial in the third quarter of 2026 and expects to provide further guidance in the second quarter of this year. ARD-101 has demonstrated an ability to reduce hunger when used alone or in combination with currently available GLP-1 therapies. The FDA has granted ARD-101 both Orphan Drug Designation and Rare Pediatric Disease Designation for Prader-Willi Syndrome.
공시 • Feb 12Aardvark Therapeutics, Inc. Announces Appointment of Executive, Effective February 9, 2026Aardvark Therapeutics, Inc. announced the appointment of Derrick C. Li as Chief Business Officer, as well as the expansion of Nelson Sun’s role to include Chief Operating Officer, in addition to his current role as Chief Financial Officer. The appointments are effective as of February 9, 2026. In Mr. Li’s new role, he will lead Aardvark's business development strategy and execution with responsibility for financing, licensing, partnership strategy and corporate development initiatives. Mr. Li is a seasoned biotechnology executive with more than 20 years of global experience in biopharmaceutical business development, investment banking and corporate strategy. Prior to joining Aardvark, he served as Chief Strategy Officer at ODC Life Sciences, a Latin America-focused clinical research organization, where he drove growth strategy and global partnerships. He has also held senior leadership roles, including Head of Strategy and Investor Relations at Cellular Biomedicine Group (now AbelZeta). Additionally, he has extensive investment banking and investment management experience, most recently, serving as a Managing Director in the Healthcare Investment Group at Robert W. Baird. Mr. Li earned a dual bachelor's degree in accountancy and finance from Villanova University.
공시 • Feb 10Aardvark Therapeutics Announces Fda Submission and Irb Approval of Amended Trial Protocol for Lead Candidate Ard-101, Expanding Eligibility in Phase 3 Study of Prader-Willi SyndromeAardvark Therapeutics, Inc. announced that Institutional Review Board (IRB) approval has been granted in the United States for an amended protocol to its ongoing Phase 3 HERO pivotal clinical trial evaluating ARD-101 for the treatment of hyperphagia in individuals with Prader-Willi Syndrome (PWS). The amended protocol, submitted to the U.S. Food and Drug Administration (FDA), lowers the minimum age of eligibility for trial participation from 10 to 7 years old. This protocol amendment reflects Aardvark's continued focus on reducing barriers to participation and expanding access for those affected by PWS, a rare genetic disorder characterized by chronic hyperphagia. Expanding eligibility reflects Aardvark's commitment to addressing the urgent need in the PWS community for a differentiated therapy and aim to ensure broad and equitable access. The Hunger Elimination or Reduction Objective (HERO) trial (NCT06828861) is a Phase 3 randomized, double-blind, placebo-controlled trial assessing ARD-101 for thetreatment of hyperphagia in patients with Prader-Willi syndrome (PWS). Aardvark plans to enroll 90 patients in this clinical trial across the U.S., Australia, Canada, the United Kingdom and South Korea. The primary endpoint is change in the Hyperphagia Questionnaire for Clinical Trials (HQ-CT) score from baseline to Week 12. Secondary outcome measures include change in Caregiver Global Impression of Severity (CaGI-S) for hyperphagia in PWS patients and change in Clinical Global Impression of Severity ("CGI-S") score for hyperphagia inPWS patients. All participants who complete the 12-week clinical trial will have the option to participate in an Open Label Extension trial. More information about the study can be found at <URL> The FDA has granted ARD-101 both Orphan Drug Designation and Rare Pediatric Disease Designation for Prader-Willi Syndrome ("PWS"). ARD-101 is being evaluated in the Phase 3 HERO trial for hyperphagia associated with PWS associated with PWS.
Recent Insider Transactions • Dec 15CEO, Secretary & Director recently bought US$101k worth of stockOn the 11th of December, Tien-Li Lee bought around 7k shares on-market at roughly US$14.49 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Tien-Li has been a buyer over the last 12 months, purchasing a net total of US$359k worth in shares.
공시 • Dec 11Aardvark Therapeutics Announces First Patient Dosed in Australia in Hero Phase 3 Trial for Prader-Willi SyndromeAardvark Therapeutics, Inc. announced that the first patient has been dosed in Australia in its Phase 3 HERO pivotal clinical trial assessing ARD-101 for the treatment of hyperphagia in individuals with Prader-Willi syndrome (PWS). Additionally, regulatory clearance for enrollment by clinical trial sites in Canada and the United Kingdom has also been received. Based on strong enrollment in the US and continued progress in advancing the clinical trial internationally, the clinical trial continues to track towards a topline data readout in third quarter 2026. US trial sites are actively enrolling, and sites in Australia started enrolling in November. The Hunger Elimination or Reduction Objective (HERO) trial (NCT06828861) is a Phase 3 randomized, double-blind, placebo-controlled trial assessing ARD-101 For the treatment of hyperphagIA in patients with Prader-Willi Syndrome (PWS). Aardvark plans to enroll 90 patients in this clinical trial across the US, Australia, Canada, the United Kingdom, and South Korea. The primary endpoint is change in the Hyperphagia Questionnaire for Clinical Trials (HQ-CT) score from baseline to Week 12. Secondary outcome measures include change in Caregiver Global Impression of Severity (CaGI-S) for hyperphagia in PWS patients and change in Clinical Global Impression of Severity ("CGI-S") score for hyperphagia inPWS patients. ARD-101 has demonstrated an ability to reduce hunger when used alone or in combination with currently available GLP-1 therapies. The FDA has granted ARD-101 both Orphan Drug Designation and Rare Pediatric Disease Designation for PWS. ARD-101 is being evaluated in the Phase 3 HERO trial for hyperphagia associated with PWS associated with PWS.
공시 • Nov 05Aardvark Therapeutics, Inc. Presents Data Supporting its Metabolic Obesity Pipeline Programs at ObesityWeek 2025Aardvark Therapeutics, Inc. presented data at the ObesityWeek 2025 conference demonstrating the mechanistic rationale and therapeutic potential of two of its metabolic obesity programs, including ARD-201. Preclinical - ARD-201 (Validated Diet-Induced Obesity (DIO) Mouse Model): ARD-201 reduced fat mass comparable to high-dose tirzepatide but, unlike tirzepatide, preserved lean mass; ARD-201 alone achieved glucose control comparable to high-dose tirZepatide, and in combination with low-dose tirzepatides delivered the most rapid glucose clearance; Previously reported preclinical data demonstrated ARD-201 reduced body weight by 19% after 30 days, which was comparable to high-dose tir Zepatide; Previously reported preclinical data demonstrates ARD-201 ~30% weight loss when combined low-dose dirzepatide; Clinical - ARD-101 (Randomized, Placebo-Controlled, Phase 2A Study in Adults with Obesity): ARD-101 showed signals of weight control, reduced hunger, and improved metabolic parameters, particularly among participants with elevated baseline values; ARD-101 was well tolerated, with no serious adverse events or treatment discontinuations, reflecting a distinct profile from the effects associated with current anti-obesity therapies; WE-868 is a small molecule isoflavonoid designed to modulate oxidative phosphorylation and represents a potentially novel pathway for promoting weight loss and additional metabolic benefits: In preclinical studies, WE-868 dose-dependently prevented high-fat diet (HFD)-induced weight gain, with the higher dose inducing net weight loss; In DIO mice, significant weight loss was seen in medium and high dose WE-868 compared to semaglutide.
공시 • Oct 08Aardvark Therapeutics Announces Fda Alignment on Protocol Amendment Expanding Phase 3 Hero Trial Population for Prader-Willi SyndromeAardvark Therapeutics, Inc. announced alignment with the U.S. Food and Drug Administration (FDA) on a protocol amendment to the company's Phase 3 HERO trial of ARD-101 for the treatment of hyperphagia associated with Prader-Willi Syndrome (PWS). The protocol amendment changes the minimum age of eligibility to participate in the trial from 13 to 10 years old. ARD-101 has demonstrated an ability to reduce hunger when used alone or in combination with currently available GLP-1 therapies. The FDA has granted ARD-101 both Orphan Drug Designation and Rare Pediatric Disease Designation for PWS. ARD-101 is being evaluated in the Phase 3 HERO trial for hyperphagia associated with PWS associated with PWS.
Recent Insider Transactions • Sep 14CEO, Secretary & Director recently bought US$161k worth of stockOn the 12th of September, Tien-Li Lee bought around 20k shares on-market at roughly US$8.03 per share. This transaction amounted to 1.3% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Tien-Li's only on-market trade for the last 12 months.
Recent Insider Transactions Derivative • Sep 01CEO, Secretary & Director exercised options to buy US$143k worth of stock.On the 28th of August, Tien-Li Lee exercised options to buy 17k shares at a strike price of around US$4.24, costing a total of US$73k. This transaction amounted to 1.2% of their direct individual holding at the time of the trade. Since December 2024, Tien-Li's direct individual holding has decreased from 2.91m shares to 1.51m. This was the only transaction from an insider over the last 12 months.
공시 • Aug 12Aardvark Therapeutics, Inc. Announces ARD-201 Preclinical Obesity Data Showing Significant Weight Loss as A Monotherapy, Enhancement of Glp-1Ra Therapy in Combination, and Effective Maintenance Following Discontinuation of Glp-1Ra TherapyAardvark Therapeutics, Inc. announced new positive preclinical data demonstrating the potential of ARD-201 for the treatment of metabolic obesity and obesity-related conditions. Data in the validated diet-induced obesity (DIO) mouse model (a conventional model recognized for its strong translational relevance in the field of glucagon-like peptide-1 receptor agonists (GLP-1RAs)) demonstrated potential applications for ARD-201, including for the attenuation of weight gain after withdrawal from GLP-1RA therapies, as a monotherapy for weight loss without GLP-1RA therapy, as well as for weight loss in combination with GLP-1RA therapy. These two focused trials will replace the previously planned EMPOWER trial and are designed to enhance the precision and clarity of data collection compared to the EMPOWER trial.
공시 • Feb 14Aardvark Therapeutics, Inc. has completed an IPO in the amount of $94.208 million.Aardvark Therapeutics, Inc. has completed an IPO in the amount of $94.208 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 5,888,000 Price\Range: $16 Discount Per Security: $1.12 Transaction Features: Reserved Share Offering; Sponsor Backed Offering
